Process for producing a solid dispersion of an active ingredient

Patent metadata

Field	Value
Publication number	US-9414992-B2
Application number	US-201314094533-A
Country	US
Kind code	B2
Filing date	Dec 2, 2013
Priority date	Mar 10, 2006
Publication date	Aug 16, 2016
Grant date	Aug 16, 2016

Abstract

A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts ( 2 ), each of the shafts ( 2 ) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element ( 14 ) which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.

First claim

We claim:

1. A process for producing a solid dispersion of a pharmaceutical active ingredient which comprises feeding the pharmaceutical active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein at least 98% by weight of the total amount of active ingredient is present in an amorphous state:
wherein the extruder comprises a housing, and at least two rotating shafts within said housing, wherein each of the shafts carries a plurality of processing elements disposed axially one behind the other, the processing elements defining
(i) a feeding and conveying section,
(ii) a first mixing section,
(iii) an intermediate conveying section,
(iv) a reverse-flight section, and
(v) a discharging section,

wherein the processing elements defining the first mixing section comprise at least one mixing element and
the processing elements defining the reverse-flight section comprise at least one mixing element and downstream thereto at least one reverse-flight element,
wherein the at least one reverse-flight element is based on a screw-type element having a conveying direction opposite to the general conveying direction of the extruder;
wherein at least one mixing element is derived from a screw-type element, has recesses formed in the screw-flight of the screw-type element, and has a plurality of concentric ring portions formed by grooves turned into the screw-type element; and
wherein the processing elements are sized and configured to provide a recurring sequence of pressure build-up that forces the pharmaceutical active ingredient through an annular gap between the extruder housing and ring portions of the mixing element with shearing action and elongation, followed by a reduction in pressure, thereby causing a defined and uniform but not undue stress on the pharmaceutical active ingredient, thereby avoiding high temperatures or high local shear forces that cause decomposition of the pharmaceutical active ingredient and preventing residues of extruded material from remaining within the extruder over extended periods of time; and
wherein said mixing elements enable a sufficient degree of mixing or homogenization with less degradation of the active ingredient or formulation of other ingredients as compared to degradation of the active ingredient or formulation of other ingredients resulting from a process employing paddle means or mixing blocks.

2. The process of claim 1 , wherein the processing elements defining the reverse-flight section comprise at least three reverse-flight elements wherein at least one positive-flight screw-type element is arranged between the respective successive reverse-flight elements.

3. The process of claim 2 , wherein the length of the positive-flight screw-type element(s) arranged between the second and third reverse-flight element is in a range from 1 to 15 times the length of the positive-flight screw-type element(s) arranged between the first and second reverse-flight elements.

4. The process of claim 1 , wherein the processing elements defining the reverse-flight section comprise at least four reverse-flight elements, wherein at least one positive-flight screw-type element is arranged between the respective successive reverse-flight elements, and wherein the positive-flight screw-type elements arranged between successive reverse-flight elements have the same length.

5. The process of claim 1 , wherein at least one reverse-flight element is positioned downstream to the mixing element(s).

6. The process of claim 1 , wherein at least one mixing element does not have a plane surface area with a normal that is parallel and opposite to the general conveying direction.

7. The process of claim 1 , wherein at least one mixing element does not have a face that is perpendicular to the general conveying direction.

8. The process of claim 1 , wherein at least one mixing element does not have abutting faces that are perpendicular to the general conveying direction.

9. The process of claim 1 , wherein at least part of the matrix-forming agent is fed to a hopper of the extruder and at least one component selected from
(i) the remainder of the matrix-forming agent,
(ii) an active ingredient,
(iii) an additive, and
(iv) combinations thereof,

is introduced into the extruder through an opening in the extruder barrel at a position upstream of or in a mixing section or reverse-flight section.

10. The process of claim 9 , wherein the at least one component is introduced into the extruder at a position at or close to the junction of the feeding and conveying section and a mixing section or reverse-flight section.

11. The process of claim 9 , wherein the at least one component is liquid or liquefied.

12. The process of claim 9 , wherein the at least one component comprises a pharmaceutically acceptable surfactant.

13. The process of claim 1 , wherein the pharmaceutical active ingredient is dispersed in a polymer in a state of a solid solution.

14. The process of claim 1 , wherein the matrix-forming agent comprises a pharmaceutically acceptable polymer.

15. The process of claim 14 , wherein the pharmaceutically acceptable polymer is selected from the group consisting of homopolymers of N-vinyl lactams, copolymers of a N-vinyl lactam and one or more comonomers selected from nitrogen-containing monomers and oxygen-containing monomers, cellulose esters and cellulose ethers, high molecular polyalkylene oxides, polyacrylates and polymethacrylates, oligo- and polysaccharides, poly(hydroxy acids), or mixtures thereof.

16. The process of claim 1 , wherein the matrix-forming agent comprises a member selected from polyols, waxes and lipids.

17. The process of claim 1 , additionally comprising feeding at least one additive selected from the group consisting of flow regulators, lubricants, fillers, disintegrants, plasticizers, stabilizers or preservatives into the extruder.

18. The process of claim 1 , wherein the extrudate is directly shaped into a dosage form.

19. The process of claim 18 , wherein shaping is carried out by calendaring, injection moulding or profile extrusion.

20. The process of claim 1 , additionally comprising grinding the solidified extrudate.

21. The process of claim 20 , additionally comprising compressing said solid dispersion product into a tablet or filling said solid dispersion product into a capsule shell.

22. The process of claim 21 , additionally comprising applying a film-coat to the tablet.

23. The process of claim 1 , wherein the extruder further comprises a barrel having several heating zones, wherein the portion of the barrel upstream of the first reverse-flight element is maintained at a lower temperature than the portion of the barrel downstream of the first reverse-flight element.

24. The process of claim 1 , wherein the processing elements defining the reverse-flight section comprise at least two reverse-flight elements and at least one positive-flight screw-type element which is arranged between said two reverse-flight elements.

25. The process of claim 24 , wherein said at least two reverse-flight elements have a screw pitch ranging from −0.5 times to −1.5 times the screw pitch of the at least one positive-flight screw-type element arranged between the at least two reverse-flight elements.

26. The process of claim 24 , wherein the said at least two reverse-flight elements have a screw pitch ranging from −0.5 time to

Assignees

• Abbott Gmbh & Co Kg
• Abbvie Deutschland

Inventors

• Kessler Thomas
• Breitenbach Jörg
• Schmidt Christoph
• Degenhardt Matthias
• Rosenberg Jörg
• Krull Harald
• Berndl Gunther

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/18

  for HIV · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• B29C48/625

  characterised by the ratio of the threaded length of the screw to its outside diameter [L/D ratio] · CPC title

• A61K9/2027

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title